Targeting cancer cells with specific enzyme inhibitors

Pro-Drug Enolase Inhibitors in Precision Oncology

NIH-funded research University of Tx Md Anderson Can Ctr · NIH-11010746

This study is exploring a new way to treat certain cancers by targeting a weakness in the cancer cells, hoping to create a treatment that can kill those cells without harming healthy ones.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Tx Md Anderson Can Ctr NIH-funded
Lab location1 site (Houston, United States)
Project IDNIH-11010746 on NIH RePORTER

What this research studies

This research investigates a novel approach to treating certain cancers by exploiting genetic vulnerabilities. It focuses on cancers that have lost a key tumor suppressor gene, leading to reliance on a related enzyme for survival. By developing a specific inhibitor for this enzyme, the research aims to selectively kill cancer cells while sparing normal tissues. The methodology includes testing this inhibitor in preclinical models to assess its effectiveness and safety.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients with cancers that have homozygous deletions of the ENO1 gene, such as certain glioblastomas.

Not a fit: Patients whose cancers do not exhibit the specific genetic deletions targeted by this research may not receive any benefit.

Why it matters

Potential benefit: If successful, this research could provide a targeted treatment option for patients with specific types of cancer that exhibit certain genetic deletions.

How similar studies have performed: This approach is innovative and has shown promising results in preclinical models, indicating potential for success in treating specific cancer types.

Where this research is happening

Houston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Anti-Cancer Agentsanti-cancer drug
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.